Imp2 regulates GBM progression by activating IGF2/PI3K/Akt pathway

References

• Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359:492-507; PMID:18669428; http://dx.doi.org/10.1056/NEJMra0708126
   PubMed Web of Science ®Google Scholar
• Sathornsumetee S, Reardon DA, Desjardins A, Quinn JA, Vredenburgh JJ, Rich JN. Molecularly targeted therapy for malignant glioma. Cancer 2007; 110:13-24; PMID:17520692; http://dx.doi.org/10.1002/cncr.22741
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987-96; PMID:15758009; http://dx.doi.org/10.1056/NEJMoa043330
   PubMed Web of Science ®Google Scholar
• Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 2004; 30:193-204
   PubMed Web of Science ®Google Scholar
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008; 455:1061-8; PMID:18772890; http://dx.doi.org/10.1038/nature07385
   PubMed Web of Science ®Google Scholar
• Fan QW, Weiss WA. Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance. Curr Top Microbiol Immunol 2010; 347:279-96; PMID:20535652
   PubMed Web of Science ®Google Scholar
• Wen PY, Lee EQ, Reardon DA, Ligon KL, Alfred Yung WK. Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro-oncology 2012; 14:819-29
   PubMed Web of Science ®Google Scholar
• Tso CL, Shintaku P, Chen J, Liu Q, Liu J, Chen Z, Yoshimoto K, Mischel PS, Cloughesy TF, Liau LM, et al. Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res 2006; 4:607-19; PMID:16966431; http://dx.doi.org/10.1158/1541-7786.MCR-06-0005
   PubMed Web of Science ®Google Scholar
• Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PtdIns, Chen H, Roix JJ, Kathiresan S, Hirschhorn JN, Daly MJ, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007; 316:1331-6; PMID:17463246; http://dx.doi.org/10.1126/science.1142358
   PubMed Web of Science ®Google Scholar
• Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, Erdos MR, Stringham HM, Chines PS, Jackson AU, et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007; 316:1341-5; PMID:17463248; http://dx.doi.org/10.1126/science.1142382
   PubMed Web of Science ®Google Scholar
• Christiansen J, Kolte AM, Hansen T, Nielsen FC. IGF2 mRNA-binding protein 2: biological function and putative role in type 2 diabetes. J Mol Endocrinol 2009; 43:187-95; PMID:19429674; http://dx.doi.org/10.1677/JME-09-0016
   PubMed Web of Science ®Google Scholar
• Boudoukha S, Cuvellier S, Polesskaya A. Role of the RNA-binding protein IMP-2 in muscle cell motility. Mol Cell Biol 2010; 30:5710-25; PMID:20956565; http://dx.doi.org/10.1128/MCB.00665-10
   PubMed Web of Science ®Google Scholar
• Dai N, Rapley J, Angel M, Yanik MF, Blower MD, Avruch J. mTOR phosphorylates IMP2 to promote IGF2 mRNA translation by internal ribosomal entry. Genes Dev 2011; 25:1159-72; PMID:21576258; http://dx.doi.org/10.1101/gad.2042311
   PubMed Web of Science ®Google Scholar
• Hammer NA, Hansen T, Byskov AG, Rajpert-De Meyts E, Grondahl ML, Bredkjaer HE, Wewer UM, Christiansen J, Nielsen FC. Expression of IGF-II mRNA-binding proteins (IMPs) in gonads and testicular cancer. Reproduction 2005; 130:203-12; PMID:16049158; http://dx.doi.org/10.1530/rep.1.00664
   PubMed Web of Science ®Google Scholar
• Himoto T, Kuriyama S, Zhang JY, Chan EK, Nishioka M, Tan EM. Significance of autoantibodies against insulin-like growth factor II mRNA-binding proteins in patients with hepatocellular carcinoma. Int J Oncol 2005; 26:311-7; PMID:15645114
   PubMed Web of Science ®Google Scholar
• Janiszewska M, Suva ML, Riggi N, Houtkooper RH, Auwerx J, Clement-Schatlo V, Radovanovic I, Rheinbay E, Provero P, Stamenkovic I. Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev 2012; 26:1926-44; PMID:22899010; http://dx.doi.org/10.1101/gad.188292.112
   PubMed Web of Science ®Google Scholar
• Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic BI. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res 2005; 65:8679-89; PMID:16204036; http://dx.doi.org/10.1158/0008-5472.CAN-05-1204
   PubMed Web of Science ®Google Scholar
• Soroceanu L, Kharbanda S, Chen R, Soriano RH, Aldape K, Misra A, Zha J, Forrest WF, Nigro JM, Modrusan Z, et al. Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma. Proc Natl Acad Sci U S A 2007; 104:3466-71; PMID:17360667; http://dx.doi.org/10.1073/pnas.0611271104
   PubMed Web of Science ®Google Scholar
• Bagci-Onder T, Wakimoto H, Anderegg M, Cameron C, Shah K. A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models. Cancer Res 2011; 71:154-63; PMID:21084267; http://dx.doi.org/10.1158/0008-5472.CAN-10-1601
   PubMed Web of Science ®Google Scholar
• Zhu Y, Shah K. Multiple lesions in receptor tyrosine kinase pathway determine glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR dual inhibitor PF-05212384. Cancer Biol Ther 2014; 15:815-22; PMID:24658109; http://dx.doi.org/10.4161/cbt.28585
   PubMed Web of Science ®Google Scholar
• Gulati N, Karsy M, Albert L, Murali R, Jhanwar-Uniyal M. Involvement of mTORC1 and mTORC2 in regulation of glioblastoma multiforme growth and motility. Int J Oncol 2009; 35:731-40; PMID:19724909
   PubMed Web of Science ®Google Scholar
• Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 2005; 24:7443-54; PMID:16288291; http://dx.doi.org/10.1038/sj.onc.1209091
   PubMed Web of Science ®Google Scholar
• Song Y, Hu Z, Long H, Peng Y, Zhang X, Que T, Zheng S, Li Z, Wang G, Yi L, et al. A complex mechanism for HDGF-mediated cell growth, migration, invasion, and TMZ chemosensitivity in glioma. J Neurooncol 2014; 119:285-95; PMID:24986090; http://dx.doi.org/10.1007/s11060-014-1512-4
   PubMed Web of Science ®Google Scholar
• Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, Polley MY, Ozawa T, Berger MS, Aftab DT, et al. Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro-oncology 2011; 13:384-92; PMID:21317208; http://dx.doi.org/10.1093/neuonc/noq193
   PubMed Web of Science ®Google Scholar
• Suvasini R, Shruti B, Thota B, Shinde SV, Friedmann-Morvinski D, Nawaz Z, Prasanna KV, Thennarasu K, Hegde AS, Arivazhagan A, et al. Insulin growth factor-2 binding protein 3 (IGF2BP3) is a glioblastoma-specific marker that activates phosphatidylinositol 3-kinase/mitogen-activated protein kinase (PI3K/MAPK) pathways by modulating IGF-2. J Biol Chem 2011; 286:25882-90; PMID:21613208; http://dx.doi.org/10.1074/jbc.M110.178012
   PubMed Web of Science ®Google Scholar
• Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307:1098-101; PMID:15718470; http://dx.doi.org/10.1126/science.1106148
   PubMed Web of Science ®Google Scholar
• Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J, Su B. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006; 127:125-37; PMID:16962653; http://dx.doi.org/10.1016/j.cell.2006.08.033
   PubMed Web of Science ®Google Scholar
• Mahajan K, Coppola D, Challa S, Fang B, Chen YA, Zhu W, Lopez AS, Koomen J, Engelman RW, Rivera C, et al. Ack1 mediated AKT/PKB tyrosine 176 phosphorylation regulates its activation. PloS one 2010; 5:e9646; PMID:20333297; http://dx.doi.org/10.1371/journal.pone.0009646
   PubMed Web of Science ®Google Scholar
• Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JK, Sawyers CL. Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci U S A 2007; 104:5563-8; PMID:17372210; http://dx.doi.org/10.1073/pnas.0609139104
   PubMed Web of Science ®Google Scholar
• So AI, Levitt RJ, Eigl B, Fazli L, Muramaki M, Leung S, Cheang MC, Nielsen TO, Gleave M, Pollak M. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clini Cancer Res 2008; 14:6944-54; PMID:18980989; http://dx.doi.org/10.1158/1078-0432.CCR-08-0408
   PubMed Web of Science ®Google Scholar
• Levitt RJ, Georgescu MM, Pollak M. PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. Biochem Biophys Res Commun 2005; 336:1056-61; PMID:16154532; http://dx.doi.org/10.1016/j.bbrc.2005.08.229
   PubMed Web of Science ®Google Scholar
• Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8:915-28; PMID:19029956; http://dx.doi.org/10.1038/nrc2536
   PubMed Web of Science ®Google Scholar
• Hulpiau P, van Roy F. Molecular evolution of the cadherin superfamily. Int J Biochem Cell Biol 2009; 41:349-69; PMID:18848899; http://dx.doi.org/10.1016/j.biocel.2008.09.027
   PubMed Web of Science ®Google Scholar
• Lau MT, Klausen C, Leung PC. E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via β-catenin-Egr1-mediated PTEN expression. Oncogene 2011; 30:2753-66; PMID:21297666; http://dx.doi.org/10.1038/onc.2011.6
   PubMed Web of Science ®Google Scholar
• Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer 2004; 4:118-32; PMID:14964308; http://dx.doi.org/10.1038/nrc1276
   PubMed Web of Science ®Google Scholar
• Schwechheimer K, Zhou L, Birchmeier W. E-Cadherin in human brain tumours: loss of immunoreactivity in malignant meningiomas. Virchows Archiv 1998; 432:163-7; PMID:9504862; http://dx.doi.org/10.1007/s004280050151
   PubMed Web of Science ®Google Scholar
• Howng SL, Wu CH, Cheng TS, Sy WD, Lin PC, Wang C, Hong YR. Differential expression of Wnt genes, β-catenin and E-cadherin in human brain tumors. Cancer Lett 2002; 183:95-101; PMID:12049819; http://dx.doi.org/10.1016/S0304-3835(02)00085-X
   PubMed Web of Science ®Google Scholar
• Asano K, Kubo O, Tajika Y, Takakura K, Suzuki S. Expression of cadherin and CSF dissemination in malignant astrocytic tumors. Neurosurg Rev 2000; 23:39-44; PMID:10809486; http://dx.doi.org/10.1007/s101430050030
   PubMed Web of Science ®Google Scholar
• Utsuki S, Sato Y, Oka H, Tsuchiya B, Suzuki S, Fujii K. Relationship between the expression of E-, N-cadherins and β-catenin and tumor grade in astrocytomas. J Neurooncol 2002; 57:187-92; PMID:12125981; http://dx.doi.org/10.1023/A:1015720220602
   PubMed Web of Science ®Google Scholar
• Perego C, Vanoni C, Massari S, Raimondi A, Pola S, Cattaneo MG, Francolini M, Vicentini LM, Pietrini G. Invasive behaviour of glioblastoma cell lines is associated with altered organisation of the cadherin-catenin adhesion system. J Cell Sci 2002; 115:3331-40; PMID:12140264
   PubMed Web of Science ®Google Scholar
• De Santis G, Miotti S, Mazzi M, Canevari S, Tomassetti A. E-cadherin directly contributes to PI3K/Akt activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells. Oncogene 2009; 28:1206-17; PMID:19151754; http://dx.doi.org/10.1038/onc.2008.470
   PubMed Web of Science ®Google Scholar
• Hasselbach LA, Irtenkauf SM, Lemke NW, Nelson KK, Berezovsky AD, Carlton ET, Transou AD, Mikkelsen T, deCarvalho AC. Optimization of high grade glioma cell culture from surgical specimens for use in clinically relevant animal models and 3D immunochemistry. J Vis Exp 2014:e51088; PMID:24429465
   PubMedGoogle Scholar
• Kessler SM, Pokorny J, Zimmer V, Laggai S, Lammert F, Bohle RM, Kiemer AK. IGF2 mRNA binding protein p62/IMP2-2 in hepatocellular carcinoma: antiapoptotic action is independent of IGF2/PI3K signaling. Am J Physiol Gastrointest Liver Physiol 2013; 304:G328-36; PMID:23257922; http://dx.doi.org/10.1152/ajpgi.00005.2012
   PubMedGoogle Scholar